Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2024 16:10 ET | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q3 2024 Financial Results

MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
October 31, 2024 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
September 24, 2024 08:00 ET | Source: Panbela Therapeutics, Inc.

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
August 13, 2024 16:10 ET | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q2 2024 Financial Results

MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
July 30, 2024 16:15 ET | Source: Panbela Therapeutics, Inc.

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
June 24, 2024 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low...
June 10, 2024 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Oral Presentation at Digestive Disease Week (DDW):

MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
May 15, 2024 16:10 ET | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q1 2024 Financial Results

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
May 06, 2024 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
May 01, 2024 16:15 ET | Source: Panbela Therapeutics, Inc.

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...